Exatecan Intermediate 1
Based on 1 Customer Validation
Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor with anticancer effects.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 100.1%
- No. CAS: 110351-94-5
- Fòrmula: C13H13NO5
- Peso molecular:263.25
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas ADC Payloads
MoreVer todos los productos específicos de isoformas Topoisomerase
More
Actividad biológica
|
Camptothecins |
Exatecan belongs to the class of camptothecin analogs. Exatecan can serve as the cytotoxic component of ADCs, disrupting tumor cell proliferation and division by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers[1][2][3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 110351-94-5
-
Appearance Solid
-
Peso molecular 263.25
-
Fòrmula C13H13NO5
-
Color Off-white to yellow
-
SMILES
O=C1[C@](O)(CC)C(C=C23)=C(CO1)C(N3CCC2=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Solvente y solubilidad
DMSO : 25 mg/mL (94.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (454 KB)
- English - EN (454 KB)
- Français - FR (454 KB)
- Deutsch - DE (454 KB)
- Norwegian - NO (454 KB)
- Español - ES (454 KB)
- Swedish - SV (454 KB)
- Italian - IT (454 KB)
- Korean - KR (454 KB)
- Portuguese - PT (454 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Weng W, et al. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13(4):950-973. [Content Brief]
[3]. Conilh L, et al. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel). 2021 Mar 9;14(3):247. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7987 mL | 18.9934 mL | 37.9868 mL | 94.9671 mL |
| 5 mM | 0.7597 mL | 3.7987 mL | 7.5974 mL | 18.9934 mL | |
| 10 mM | 0.3799 mL | 1.8993 mL | 3.7987 mL | 9.4967 mL | |
| 15 mM | 0.2532 mL | 1.2662 mL | 2.5325 mL | 6.3311 mL | |
| 20 mM | 0.1899 mL | 0.9497 mL | 1.8993 mL | 4.7484 mL | |
| 25 mM | 0.1519 mL | 0.7597 mL | 1.5195 mL | 3.7987 mL | |
| 30 mM | 0.1266 mL | 0.6331 mL | 1.2662 mL | 3.1656 mL | |
| 40 mM | 0.0950 mL | 0.4748 mL | 0.9497 mL | 2.3742 mL | |
| 50 mM | 0.0760 mL | 0.3799 mL | 0.7597 mL | 1.8993 mL | |
| 60 mM | 0.0633 mL | 0.3166 mL | 0.6331 mL | 1.5828 mL | |
| 80 mM | 0.0475 mL | 0.2374 mL | 0.4748 mL | 1.1871 mL |
Exatecan Intermediate 1 Related Classifications
HY-42487 Related Classifications
Powered by Bioz